Chairman's Message

Welcome to the Royer Biomedical, Inc. Website.

Since 1997, RBI has worked to develop novel, resorbable time-release products. Our efforts have been validated on various levels including clinical results, patent issuances, the involvement of top orthopedic physicians and veterinarians in the Company's direction and activities, and the positive responses that we have received regarding institutional collaborations. Royer Animal Health, LLC, currently offers three products based on Matrix III and R-Gel technologies. MIII Cisplatin Beads have changed the treatment paradigm for equine cancer. Moreover, clinical studies with companion animals and MIII Cisplatin Beads look very promising.

We believe that each of our technology platforms represents an improvement over other chemical matrix systems and techniques currently used in drug delivery. In some cases, these platforms are expected to be enabling. A total of five (5) US Patents have been issued to the Company.

Near term goals include filing a 510(k) application on R-Gel Antibiotic, filing an IND for R-Gel 5-FU and filing an IND for R-Gel Bupivacaine for treatment of post surgical pain. In veterinary medicine we will launch promotional efforts for MIII Cisplatin Beads, R-Gel Antibiotic, and MIII Antibiotic Beads.